• PDF / 169,566 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 9 Downloads / 132 Views

DOWNLOAD

REPORT

---

1 S

Clinically relevant non-major bleeding and major bleeding: 2 case reports In a post-hoc analysis of a prospective observational cohort study, involving 310 consecutive patients hospitalised with acute pulmonary embolism (APE) at a single reference center in Poland between January 2013 and June 2017, 2 patients [ages and sexes not stated] were described, who developed clinically relevant non-major bleeding or major bleeding during treatment with alteplase or dabigatran-etexilate [dabigatran] [routes, dosages and durations of treatments to reactions onsets not stated; not all outcomes stated]. The patients were presented to the emergency department. Based on contrast-enhanced MSCT, the patients were diagnosed with APE and subsequently hospitalised. Plasma D-dimer concentrations were quantitatively measured on the day of admission to the emergency department. Following admission, the patients started receiving alteplase (n=1) or dabigatran-etexilate (n=1). However, the patient receiving dabigatran-etexilate developed clinically relevant non-major bleeding, while the patient receiving alteplase developed major bleeding and eventually died [immediate cause of death not stated], for which no follow-up autopsy was performed. Skowronska M, et al. D-dimer levels enhance the discriminatory capacity of bleeding risk scores for predicting in-hospital bleeding events in acute pulmonary embolism. 803497615 European Journal of Internal Medicine 69: 8-13, Nov 2019. Available from: URL: http://doi.org/10.1016/j.ejim.2019.08.002

0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 22 Aug 2020 No. 1818